Jeito I Fund

https://www.jeito.life

Founded in 2018 and launched in January 2020 by Rafaèle Tordjman, JEITO CAPITAL, a portfolio management company approved by the Autorité des marchés financiers under number GP-19000043, is an independent investment company specialising in private equity. JEITO CAPITAL's mission is to identify and support the next generation of pioneering entrepreneurs in the field of medical innovation, through the implementation of a continuous model of significant financing aimed at accelerating time to market. Through its first fund, JEITO I, JEITO CAPITAL offers its investors the opportunity to support the growth of some fifteen start-ups with the potential to become future unicorns. The new investment company brings together a team of international experts in the drug value chain, combining scientific expertise, clinical development, patent protection and marketing. *

	Start	2020-01-15 closing
	Group	Jeito Capital (Group)
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Tordjman, Rafaèle (Jeito Capital 201806– President + Founder before Sofinnova Partners 2001–2017)
	Person 2	Clancy, Annette (Enyo Pharma 201806 Chair of Board of Directors)

	Region	Paris
	Country	France
	Street	33 rue La Fayette
	City	75009 Paris
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	200,000,000 (fund size (2020) 2020-01-15)

		* Document for ï¿½About Sectionï¿½: Jeito Capital. (1/15/20). "Press Release: Rafaèle Tordjman Launches Jeito Capital, a New Private Equity Company Dedicated to Biotech-biopharmaceuticals, and Announces the Closing of Jeito I at €200 Million". Paris.

		Record changed: 2021-09-25